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ABSTRACT 
Analysis of organic acids in urine is a valuable tool in the diagnosis of the inborn 
errors of metaboli sm known as organic acidurias. This test is commonly ordered in 
newborns with symptoms such as lethargy, failure to thrive, hepatic failure, and 
suspected familial disorders. A drawback of published methods is the overwhelming 
amount of data to examine for each patient, prior to the final laboratory report. 
Physicians will wait as long as two weeks for these time critical results. The goal of this 
research was to develop an expert system to automate the process of screening for 
metabolic disorders of urine organic acids. 
The Xaminer® pattern recognition software (ThermoFinnigan, San Jose, CA) was 
adapted to predict and identify patterns of urine organic acid disorders. The gas 
chromatography-mass spectrometry (GC-MS) full scan spectra of organic acids were 
used to build the pattern match library and train the software to recognize methylmalonic 
aciduria (MMA) and associated vitamin B12 deficiency, as well as, a subset of fatty acid 
oxidation defects (FAOD), including medium chain acyl-CoA dehydrogenase (MCAD) 
deficiency. Patient data files were de-identified and reprocessed using the expert system. 
The expert system results were compared to the original laboratory findings. 
From a total of2573 samples, the original laboratory findings were 20 positives 
for MMA and 29 positives for F AOD. The Xaminer software identified 17 of the 20 
MMA positives, plus 4 additional candidate samples that matched the search pattern 
criteria. The software found 26 of the 29 F AOD positives. Five additional sanlples were 
found to be candidates for F AOD. Software analysis time averaged less than 10 seconds 
per sample. 
This expert system can use pattern recognition of full scan GC-MS data to aid in 
patient screening for MMA and fatty acid oxidation disorders. The performance of 
Xaminer shows promise for refining or expanding the reference library to include other 
nletabolic disorders as well. 
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INTRODUCTION 
Metabolic diseases arise from inherited errors of biological pathways. The 
symptoms are normally due to a buildup of a biosynthetic precursor or product that the 
body cannot excrete. Although individual metabolic diseases are rare, their cumulative 
effect is quite comn10n. One recent review states that 1 in 3,500 infants born in the 
United States is affected by an inborn error of metabolism (1). 
Pathologic changes in normal catabolism of amino acids, carbohydrates, biogenic 
amines, and steroids often results in abnormal excretion patten1s of organic acids. These 
disorders manifest themselves either by excretion of organic acids that are normally not 
present in healthy individuals, or excretion of massive amounts of acids which are 
nonnally present only in low concentrations. Comn10n indications for organic acid 
screening include clinical situations such as an acute life-threatening episode, metabolic 
acidosis or hyperammonemia, failure to thrive, recurrent vomiting, neurological 
deterioration, or following therapy for a specific inbon1 metabolic error. 
Laboratory methods for identifying such disorders utilize gas chromatography 
(GC), high performance liquid chromatography (HPLC), gas chromatography-mass 
spectrometry (GC-MS), and liquid chromatography-mass spectrometry (LC-MS) 
instnlments. The principal method for urinary organic acid analysis remains GC-MS. 
Both liquid-liquid and solid-phase extraction techniques have been used for sample 
cleanup. The majority of methods employ derivatization to convert the organic acids into 
their volatile derivatives. Instrument run times for previously reported GC-MS methods 
range up to 60 minutes or longer per sample (2,3). 
Recent advances in the field of capillary gas chromatography, such as microbore 
columns, derivatization, fast temperature programming, and improved computer 
perfonnance allows a significant reduction in analysis time without compromising 
chromatographic resolution. Current laboratory methods are simple, fast, reproducible, 
and do not require frequent instrument maintenance. Over 150 clinically important 
organic acids can be identified in a 13-nlinute run (4). 
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The remaining limitation of current methods, however, is the time required to 
analyze the large amount of clinical data gathered in each sample run. The interpretation 
of the organic acid screen data is very labor intensive and requires extensive training and 
experience. Only a few laboratories offer this type of testing, and require a resident expert 
on staff to report results back to the client. Physicians will often wait as long as two 
weeks for a final urine organic acid report. 
The goal of this project was to develop an expert system to automate the process 
of identifying metabolic disorders from urine organic acid profiles. The software was 
intended to aid in interpretation, not to replace human judgement. This is a very complex 
assay, and involves very demanding interpretation. 
The scope of this project was to adapt and evaluate an existing pattern recognition 
software package for utility in matching organic acid disorders. The Xaminer® software 
(ThennoFinnigan, San Jose, CA) was originally designed to perfornl in the setting of 
arson investigation. It was developed to identify the GC-MS patterns of accelerants and 
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suspected compounds used to start a fire. The aim of this study was to test the feasibility 
of using the same software algorithn1s to detect patterns of urine organic acids by their 
GC-MS spectra, and to diagnose metabolic disorders by using this pattern recognition. In 
order to narrow the focus of the project, a representative single acid disorder -
methylmalonic aciduria (MMA), and n1ultiple acid disorder - fatty acid oxidation defects 
(FAOD) were evaluated. If the software was shown to perfonn well on this initial set of 
disorders, the Xaminer pattern library could then be expanded to cover a more 
comprehensive set of organic acidurias. This expert system would aid in the labor 
intensive process of chromatographic interpretation of the organic acid disorders in urine. 
Because the intent of the pattern match software was to serve as a screening tool, 
the set of positives used to build the Xaminer pattern library contained samples with 
concentrations of methylmalonic acid equal to 80 IlmollL and higher. This concentration 
of methyl malonic acid is more consistent with vitamin B12 deficiency and not a true 
methylmalonic aciduria (5). Pattern library entries for the fatty acid oxidation disorders, 
included patterns for varying types of fatty acid oxidation disorders, including short chain 
(SCAD), MCAD, and long chain (LCHAD) acyl-CoA dehydrogenase deficiencies. 
METHODS 
Samples submitted for the testing were analyzed for creatinine and the volume to 
be extracted adjusted according to sample creatinine concentration. This was done by 
calculating aliquot volume = 11.3 I concentration of creatinine in mg/dL. Thus, the 
extraction volume for each specimen was adjusted to contain 1 ~mole of creatinine. 
Because the injection volume of each sample was the same used for the calibration, the 
concentration of an acid in each sample can be quantified in mmol/mol creatinine. 
Internal standard and hydroxylamine were added to the calibrator, control, and 
patient samples. Water was added to the samples to bring the volume to 10 mL. The 
samples were then transferred into anion exchange solid phase extraction (SPE) columns 
preconditioned with nlethanol and water. The SPE columns were washed to remove 
co extracted extraneous materials, dried, and the extracted compounds were eluted. The 
eluent was evaporated, and the residues derivatized. To eliminate the formation of 
multiple peaks and to prevent the possible decarboxylation of alpha ketoacids during 
extraction, a two-step derivatization of oxime and silyl ester formation was used. After 
derivatization, each sample was transferred to an autosampler vial, and the aliquots were 
injected into the GC-MS. A representative GC-MS full scan chromatogram of urine 
organic acids is shown in Figure 1. 
The analysis was perfomled using a Finnigan Voyager GC-MS, equipped with an 
A220S autosampler and Xcalibu/M software (Thermo quest, San Jose, CA). 
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Figure 1. Gas chromatography-mass spectrometry (GC-MS) full scan 
chron1atogran1 of extracted patient sample showing organic acids in urine. 
The labeled peaks are: (1) lactic acid, (2) methylmalonic acid, (3) levulinic 
acid, (4) acetylglycine, and (5) arachidonic acid. The internal standard (2-
oxohexanoic acid) is at retention time 5.87. 
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Data acquisition was in both full scan and selected ion monitoring (SIM) mode 
using electron ionization with the detector at 350 mY. The GC was equipped with an 
RTX-l capillary column, 20 meter length, 0.18 mm diameter, and 0.40 J.lm film thickness 
(Restek, Bellafonte, PA). The instrument was tuned using perflurotributylamine. 
Data analysis was performed with two methods: full scan and SIM. The full scan 
method selected the 80 largest peaks in a chromatogram, integrated the peaks, performed 
a library search, and identified the three best matches in the libraries for each of the peaks 
in the unknown mass spectra. In addition to the full scan data analysis, quantitation for a 
total of 36 organic acids was also performed using different SIM programs. Prior to 
reporting test results, the data for each sanlple are evaluated first, by a staff technician, 
and then by the laboratory medical director. Human interpretation was assumed to be the 
gold standard. 
Since Xaminer relies on accurate peak identification and match quality of full 
scan mass spectral data, the GC-MS full scan library was a crucial step in the software 
process. Two existing libraries of organic compounds were available for use. A third 
library was custom built by full scan analysis of organic acid reference standards. The 
three GC-MS full scan libraries combined contain mass spectral data for more than 400 
unique compounds 
Data files (n 2573) for which urine organic acid screening had been performed 
by GC-MS, were collected for 18 months. All patient data files were de-identified before 
reprocessing by the Xaminer software. This research was approved by the Institutional 
Review Board of the University of Utah Health Sciences Center (IRB #9102). 
7 
After GC-MS data acquisition, Xaminer performed its own analysis to 
"fingerprint" or match and report the identity of complex samples. Software training was 
done by using the data files of previously assayed patient samples with known disorders. 
Sets of positive samples were chosen for both MMA (n 20) and F AOD (n 29) and the 
chromatographic data entered into the Xaminer software pattern library. Pattern 
recognition parameters of peak weighting and match quality threshold were optimized for 
both MMA and the fatty acid oxidation disorders. The expert system was then tested 
against the entire set of2573 data files. The goal of the project was to readily identify a 
predefined set of disorders, including a single acid disorder (MMA) and a n1ultiple acid 
disorder (FAOD). 
The results from the expert system were compared to the previously reported lab 
findings. The accuracy of identifying unknown organic acids and the precision 
(reproducibility) of the expert system were studied. Pattern match thresholds of 950/0, 
85%, 65%, and 50% were observed for both MMA and FAOD. In a separate experiment, 
a new set of unknown samples (n = 400) was processed against the Xaminer pattern 
library and the results recorded. Using the set of 400 unknowns, the size of the training 
set (n 2, 5, and 20) was also studied for MMA. An evaluation of time saved by 
Xaminer interpreting the GC-MS full scan data was also produced. Laboratory statistics 
commonly used for evaluation of assay performance are displayed in Figure 2. 
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Figure 2. Laboratory statistics used for evaluation of assay perfonnance. 
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RESULTS 
In the original 2573 samples, laboratory findings were 20 positives for MMA and 
29 positives for fatty acid oxidation disorders. Using a pattern match threshold of 800/0, 
the Xaminer software identified 17 of the 20 MMA positives, plus 4 additional candidate 
samples that matched the search pattern criteria. Table 1 shows the detailed performance 
of the Xaminer software resulting in 17 true MMA positives identified, with 4 false 
positives and 3 false negatives. Again, using a pattern match threshold of 80%, the 
Xaminer software found 26 of the 29 FAOD positives in the set of2573 samples. Five 
additional samples were found to be candidates for fatty acid oxidation disorders. Table 
1 also shows the summary of the software resulting in 26 true FAOD positives identified, 
with 5 false positives and 3 false negatives. To insure the accuracy of the pattern match 
results by Xaminer, the discrepant false positives and false negatives were independently 
verified. 
Results for both MMA and fatty acid oxidation disorders with varying thresholds 
of pattern match quality (95%, 80%, 65%, and 50%) are displayed in Table 2. Results for 
the set of 400 unknown samples are summarized in Table 3, with pattern match 
thresholds of 800/0, 650/0,50% , and 10% compared. The results of the MMA training size 
set (n = 2, 5, and 20) is shown in Table 4. Xaminer pattern matching for MMA is shown 
in Figure 3, and for MeAD in Figure 4. 




























2 The laboratory findings are assumed to be the gold standard. 
3 Pattern match threshold of 80% was used. 
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Table 2. Xaminer results for MMA and F AOD at varying match thresholds. l 
MMA2 950/0 match 800/0 nlatch 650/0 match 50% match 
Agreement 99.4 99.6 99.0 98.4 
Sensitivity 38.1 80.9 80.9 100.0 
Specificity 100.0 99.8 99.1 98.3 
+ Prediction 88.8 80.9 44.7 32.7 
- Prediction 95.7 99.8 99.8 100.0 
FAOD3 95% match 80% match 650/0 match 50% match 
Agreement 99.2 99.6 97.1 95.9 
Sensitivity 41.3 89.6 93.1 100.0 
Specificity 99.9 99.8 97.1 95.9 
+ Prediction 85.7 83.8 27.2 21.9 
- Prediction 99.3 99.8 99.9 100.0 
Total samples was 2573. 
2 Xaminer results for MMA as compared to the original laboratory findings. 
3 Xaminer results for FAOD as compared to the original laboratory findings. 
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Table 3. Xaminer results at varying match thresholds for unknown samples. 1 
80% match 65% match 50% match 10% match 
Agreenlent 98.7 97.0 96.7 79.2 
Sensitivity 66.7 77.7 88.9 100.0 
Specificity 99.4 97.4 96.9 78.7 
+ Prediction 75.0 41.1 40.0 9.7 
- Prediction 99.2 99.7 99.7 100.0 
FAOD3 80% match 65% match 50% match 10% match 
Agreement 98.7 98.2 97.3 71.2 
Sensitivity 50.0 50.0 75.0 75.0 
Specificity 99.4 98.7 97.4 71.7 
+ Prediction 40.0 28.5 23.1 2.6 
- Prediction 99.4 99.4 99.5 99.6 
Total samples was 400, including 9 MMA and 4 F AOD cases. 
2 Xaminer results for MMA as compared to the original laboratory findings. 
3 Xaminer results for F AOD as compared to the original laboratory findings. 
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Table 4. Xaminer results at varying training set size for MMA.l 
MMA2 set = 5 set = 20 
True Positives 3 4 8 
True Negatives 389 388 379 
False Positives 2 3 12 
False Negatives 6 5 1 
Total sanlples was 400 unknowns. 
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Figure 3. Xaminer spectrogram and inverted pattern match for 
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Figure 4. Xaminer spectrogram and inverted pattern match for medium 
chain acyl-CoA dehydrogenase (MCAD) deficiency. 
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The average daily workload in the clinical laboratory was 20 to 30 samples. Data 
analysis for each patient took between 20 to 30 minutes. The medical director spent 
another 10 to 15 minutes per patient report. The overall time spent per each sample was 
therefore 30 to 45 minutes. For a run of 20 patient samples, an average of 10 hours of 
chromatographic interpretation was required prior to releasing laboratory results. The 
Xaminer software could complete the pre-screen for MMA and fatty acid oxidation 
disorders in less than 10 seconds per patient sample. These results are summarized in 
Table 5. 
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Table 5. Time requirement for chromatographic interpretation of urine organic acids. 1 
Interpretation 
Time require for 1 positive sample 
Time require for 1 negative sample 









< 5 minutes 
2 Reported times are averaged for daily workload of approximately 20 samples. 
DISCUSSION 
The Xaminer® pattern recognition software is a tool to provide an automated data 
collection, library building and chromatographic pattern matching solution for GC-MS 
users. Typical applications of the Xaminer software have been arson investigation, 
perfumes and fragrance characterization, seized drug authentication (cocaine, heroine, 
etc.), forensic paint analysis, characterization of bacteria and yeasts, and oil spill 
pollution monitoring. The real world applications are generally associated with large 
numbers of samples containing many common compounds but in varying abundance. 
There may be thousands of samples, with hundreds of components, each with very minor 
differences in relative abundance. This task often requires time intensive expert data 
review and can be aided by computerized patten1 matching of extracted ion 
chromato grams. 
The Xaminer software allows identification of complex mixtures by n1atching 
chromatogram traces of unknown samples with known reference standards. Xaminer 
automates and accelerates pattern matching by allowing the user to compile a library of 
reference materials. Each material is analyzed for target components and relative 
intensity information is compiled to construct a fingerprint or "spectrogram" of the 
sample. An unknown sample may then be searched against this library, based on its own 
automatically generated spectrogram. Detected component peaks are mapped as arrays 
of relative abundances, but no longer tied to a time axis. Instead, each peak is allocated a 
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component number by Xaminer. This forms Xaminer's sample fingerprint for a specific 
mixture. Due to the proprietary nature of the software, technical details of the actual 
pattern searching and match algorithms are not readily available. 
The overwhelming amount of data per injection remains a significant challenge to 
routine laboratory analysis. The same pattern algorithm can be mathematically applied to 
each patient chromatogram. This is more objective than the human eye scrutinizing each 
sample report, and therefore produces consistent, nonsubjective results. Since 80% to 
90% of samples that are submitted for testing are determined to be negative, samples that 
were screened negative by the expert software, could be directly reviewed by the medical 
director and results reported on the san1e working day. It should noted, however, that the 
comparison of time saved was an estimation of Xaminer searching for two types of 
disorders only, while the human counterpart was looking for all plausible disorders. 
Interesting to note was the effects of lowering Xaminer's pattern match threshold 
setting. As the match threshold was decreased, a higher percent of false positives was 
produced. However, to err on the side of caution, a laboratory would likely choose to 
operate at a lower match threshold to insure that the initial screen identified all positive 
samples. In order to recognize all positive MMA and F ADD samples in the training sets, 
Xaminer required a match threshold setting of 50%. Using the 400 unknowns, match 
threshold settings were decreased in 100/0 incren1ents until 100% sensitivity for MMA 
was achieved. However, 100% sensitivity for F ADD was not attained. Training set sizes 
of n = 2 and n = 5 did not sufficiently represent positive MMA samples. The training set 
of n = 20 improved the MMA pattern match performance. 
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It would be impossible to predict that Xarniner would perform well to identify 
every known organic acid disorder, including children of differing age and nutritional 
condition. This would require that the Xaminer pattern library contain perhaps multiple 
entries for every possible cOlYtbination of variables such as patient age, drug therapy, and 
nutritional status for each known metabolic disorder (6). However, assuming that such a 
complete library could be constructed in Xaminer, a remaining complication is the 
inability of Xaminer to identify new or yet unknown disorders. Such a disorder would 
likely be misidentified as "normal" and disregarded as clinically insignificant. 
One possible strategy is to train the Xaminer system to screen for normal or 
negative samples, instead of looking for all positive acid disorders. This "rule out" 
screening strategy has been successful in cervical cytology, and may prove useful in the 
diagnoses of metabolic disorders as well (7). 
CONCLUSIONS 
Analysis of organic acids in urine is a valuable tool in the diagnosis of the inborn 
errors of metabolism known as organic acidurias. The need to separate, detect, and 
quantify a large nUluber of organic acids results in long instrument run times of 40 to 60 
minutes per sample. An improved GC-MS method can identify more than 150 important 
urine organic acids in 13 minutes. However, the remaining limitation of published 
procedures is low throughput, due to the labor-intensive identification of organic acids in 
each sample chromatogram. 
The overall performance of the Xaminer software was surprisingly good. 
However, the inability to reliably screen with 100% sensitivity, precludes this system 
from being useful in a clinical laboratory setting. Notable, was the large majority of 
samples (800/0 to 90% negative) that can be quickly screened and reported by the 
laboratory. The smaller subset of presun1ptive positive aciduria samples could then be 
the focus of the laboratory staff. Unfortunately, without known patterns entered into the 
library, new and yet unknown disorders would likely be misclassified as normal. This 
expert system can use pattern recognition of full scan GC-MS data to aid in patient 
screening for MMA and fatty acid oxidation disorders. The performance of Xaminer 
shows promise for refining or expanding the reference library to include other metabolic 
disorders. 
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